Nuclear Medicine Companies

Name: Global Nuclear Medicine Market Size, Share, Growth Analysis, By Product type(Diagnostic (SPECT AND PECT), Therapeutic (Alpha Emitters and Beta Emitters)), By Application(Cardiology Neurology, Oncology) - Industry Forecast 2023-2030
Brand: SkyQuest Technology
Price: 5300 USD
Availability: InStock

Nuclear Medicine Market Competitive Landscape

The market is competitive with several market players adopting strategic collaborations in emerging economically favorable regions, contributing to the research and development.

For instance, curium announced the acquisition of IASON (Australian based pharmaceutical company) expanding its impression in Europe.

Furthermore, the regions such as Latin America and the Middle East and Africa are representing considerable growth due to the rise in the healthcare expenditure and increase in the awareness regarding diagnostic and therapeutics for managing critical care disorders.

Top Players in the Global Nuclear Medicine Market

GE Healthcare (US)
Siemens Healthineers (Germany)
Philips Healthcare (Netherlands)
Cardinal Health (US)
Bracco Imaging (Italy)
Eckert & Ziegler (Germany)
Lantheus Medical Imaging (US)
Jubilant Life Sciences (India)
IBA Molecular (Belgium)
Norgine B.V. (Netherlands)
FUJIFILM Holdings Corporation (Japan)
Bayer Healthcare (Germany)
Theragnostics (UK)
RadioMedix Inc. (US)
Ion Beam Applications S.A. (IBA) (Belgium)
Novartis AG (Switzerland)
GLOBAL MEDICAL SOLUTIONS (US)
ISOTOPE JSC (Russia)
SHINE TECHNOLOGIES, LLC (US)
ISOTOPIA MOLECULAR IMAGING LTD. (Israel)
BWXT MEDICAL LTD. (Canada)

Nuclear Medicine Market

FAQs

Global Nuclear Medicine Market size was valued at USD 8.4 Billion in 2022 and is poised to grow from USD 10.2 Billion in 2023 to USD 22.23 Billion by 2031, at a CAGR of 13.00% during the forecast period (2024-2031).

The market is competitive with several market players adopting strategic collaborations in emerging economically favorable regions, contributing to the research and development. 'GE Healthcare (US) ', 'Siemens Healthineers (Germany) ', 'Philips Healthcare (Netherlands) ', 'Cardinal Health (US) ', 'Bracco Imaging (Italy) ', 'Eckert & Ziegler (Germany) ', 'Lantheus Medical Imaging (US) ', 'Jubilant Life Sciences (India) ', 'IBA Molecular (Belgium) ', 'Norgine B.V. (Netherlands) ', 'FUJIFILM Holdings Corporation (Japan) ', 'Bayer Healthcare (Germany) ', 'Theragnostics (UK) ', 'RadioMedix Inc. (US) ', 'Ion Beam Applications S.A. (IBA) (Belgium) ', 'Novartis AG (Switzerland) ', 'GLOBAL MEDICAL SOLUTIONS (US) ', 'ISOTOPE JSC (Russia) ', 'SHINE TECHNOLOGIES, LLC (US) ', 'ISOTOPIA MOLECULAR IMAGING LTD. (Israel) ', 'BWXT MEDICAL LTD. (Canada)'

Most cases are preventable through early detection and treatment; nuclear medicine plays an important role in these areas. Cancer was the leading cause of death in 2020, accounting for nearly 10 million deaths, according to the WHO. By 2025, 19.3 million new cancer cases per year are expected to be reported worldwide. According to the WHO, 17.9 million people died from CVD in 2019, accounting for 32% of all deaths worldwide. By 2030, this figure is expected to rise to 23.3 million. Because nuclear medicine is used to diagnose and treat diseases, the rising prevalence of these diseases is expected to drive growth.

Advancements in the Nuclear Medicine Therapies: Companies in the market are constantly focusing on the development of nuclear medicine therapies. The clinical effects of this treatment option in comparison to other therapies are driving its global demand. Furthermore, factors such as the sophistication of therapeutic application outcomes in the treatment of cancer and other disorders are expected to drive demand for nuclear medicine therapies in countries with a high cancer burden. For example, the US FDA granted Curium a Study May Proceed letter to begin its Phase-III trial with its investigational product, lutetium Lu 177 PSMA I&T. It is a radiopharmaceutical that binds to the protein Prostate-Specific Membrane Antigen (PSMA). Similarly, many market participants are developing new therapeutic products to treat a variety of medical conditions, which is driving market growth.

North America is the largest region in the nuclear medicine market and has a share of about 45.1% and is anticipated to grow add a considerable rate during the forecasted period. Due to the increased investment in R&D activities, high volume of nuclear medicine procedures, and strong health infrastructure is contributing towards the high market share of this region. For instance, Eckert and Ziegler made a development plan for cGMP facility in U.S. for contract manufacturing of radiopharmaceuticals. It will help in the production of late investigational stage and commercial stage radioisotopes which are used in nuclear medicine and help in contributing to the increasing demand for radionuclides in the market.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Nuclear Medicine Market Competitive Landscape

Nuclear Medicine Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Nuclear Medicine Market Competitive Landscape

Nuclear Medicine Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Nuclear Medicine Market?

Who are the key vendors in the Nuclear Medicine Market?

What is the key driver of Nuclear Medicine Market?

What is the key market trend for Nuclear Medicine Market?

Which region accounted for the largest share in Nuclear Medicine Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300